Sucraid. Possibly the biggest pain point in this entire community - at least obtaining it is. Most of us know how hard it is to get a Sucraid prescription insured, especially full-time. A lot of the people that manage to get any at all only get a few months out of the year covered. There are many reasons why Sucraid is so hard to get, but in this article we’ll explore the way the drug was approved for use and how that interacts with insurance policy to make coverage so difficult.
To understand why many insurance companies deny coverage so quickly, we first have to look at what exactly the drug is approved for. This matters because the FDA claim for what Sucraid treats is purposely narrow, which is part of the reason it’s so hard to get. Per the FDA, Sucraid is approved to treat a singular disease; Congenital Sucrase-Isomaltase Deficiency (CSID). This means other conditions, like acquired (secondary) sucrase deficiency or adult-onset “genetic” sucrase deficiency don’t meet these parameters. At first glance, that distinction feels arbitrary. But distinctions like that can influence coverage for expensive specialty medicines. Sucraid is no exception. The unfortunate reality is that insurance providers may determine the medicine is not a “medical necessity" because the patient doesn’t fit the parameters of the extremely narrow treatment claim. And even if you can prove it is genetically inherited, insurance providers can deny Sucraid anyway because it’s so expensive. In some cases, plan documents outline categories of high-cost medications that may be excluded from coverage or require lower-cost alternatives, rather than guaranteeing coverage regardless of price.
The previous paragraph begs another question - why is Sucraid only approved for the congenital variation of sucrase-isomaltase deficiency? (The answer to this question actually has nothing to do with insurance companies.)
Sucraid’s treatment designation is to “treat symptoms of Congenital Sucrase Isomaltase Deficiency” because any expanded claims would be way too messy for the manufacturer to get approved. Since the congenital mutation is a clean, irreversible diagnosis, it made the most sense for the manufacturer to make a treatment for exactly that claim. Sucraid is also an orphan drug (a drug for a disease affecting less than 200,000 people) with an exact treatment designation, which is why we don’t yet have over-the-counter versions using the same manufacturing process.
What is probably the most important answer to this question ties back into why the manufacturer decided not to try and treat all variations of sucrase deficiency in the first place. In secondary deficiencies, sucrase expression is typically blunted as a byproduct of an underlying issue. If you treat a secondary deficiency patient with Sucraid, you’re managing the symptoms instead of the disease itself. There’s also the possibility that the patient may recover normal enzyme activity. “So why treat a patient that might get better?” That’s not to say that you shouldn’t treat that patient (you should), but that is an example of a legitimate logistical question that manufacturers have to think about. There are also other variable factors specific to secondary deficiencies like possible recovery timelines, how the involvement of other brush border enzymes affects the acquired deficiency, underlying causes, etc. that make it much harder to obtain reliable results when gathering data for approval (which is why I said they’d probably still be researching variables and trying to get it approved to this day).
Also, adult-onset (known as “genetic” deficiencies more recently) simply were less understood when the patent was first filed. At that time, the target population was parents whose newborn children presented with symptoms after solid food containing sucrose was introduced into their diets. That’s exactly why the wording is precisely “congenital deficiency”. Overall, genetic (adult-onset) and secondary deficiencies add layers of complexity, making expanded claims much harder to satisfy.
In this section, I’ll synthesize everything mentioned above and explain why access is so limited.
Insurance providers decide who gets coverage based on the approved FDA treatment claim and “medical necessity". They rely on specific coverage criteria, making medicines with narrow claims like Sucraid easier to deny if a patient doesn’t fall within the exact treatment parameters. In other cases, the cost alone gives providers grounds to deny coverage. Sucraid is also notorious for how hard it is to get, so many physicians and gastroenterologists simply recommend dietary management as a more effective way to manage sucrase deficiency. The narrow treatment parameters can make it hard for prescribers to justify a prescription as well, especially given that secondary deficiencies typically stem from underlying issues. Prescription hesitancy is certainly a real thing, especially if the prescriber has already battled with insurance providers before. In reality, access is not limited due to a single factor. It’s a result of multiple variables, including regulatory approval, clinical variability, and structured coverage systems.
Sucraid is hard to obtain because it was approved for a very specific, lifelong condition, and everything outside the exact parameters becomes harder to justify within structured systems like insurance and prescribing.